Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Firefly Neuroscience (AIFF) Capital Expenditures (2016 - 2025)

Firefly Neuroscience has reported Capital Expenditures over the past 14 years, most recently at $23000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $23000.0 for Q4 2025, down 71.25% from a year ago — trailing twelve months through Dec 2025 was $128000.0 (down 13.51% YoY), and the annual figure for FY2025 was $128000.0, down 13.51%.
  • Capital Expenditures for Q4 2025 was $23000.0 at Firefly Neuroscience, down from $86000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for AIFF hit a ceiling of $301842.0 in Q4 2022 and a floor of $4000.0 in Q3 2024.
  • Median Capital Expenditures over the past 4 years was $19260.0 (2022), compared with a mean of $58777.1.
  • Biggest five-year swings in Capital Expenditures: surged 2096.17% in 2022 and later crashed 81.25% in 2025.
  • Firefly Neuroscience's Capital Expenditures stood at $13744.0 in 2021, then surged by 2096.17% to $301842.0 in 2022, then tumbled by 73.5% to $80000.0 in 2024, then plummeted by 71.25% to $23000.0 in 2025.
  • The last three reported values for Capital Expenditures were $23000.0 (Q4 2025), $86000.0 (Q3 2025), and $12000.0 (Q2 2025) per Business Quant data.